Carson Allaria Wealth Management, Ltd. Biocryst Pharmaceuticals Inc Transaction History
Carson Allaria Wealth Management, Ltd.
- $180 Million
- Q2 2025
A detailed history of Carson Allaria Wealth Management, Ltd. transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Carson Allaria Wealth Management, Ltd. holds 530 shares of BCRX stock, worth $4,399. This represents 0.0% of its overall portfolio holdings.
Number of Shares
530
Previous 530
-0.0%
Holding current value
$4,399
Previous $3,000
33.33%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding BCRX
# of Institutions
298Shares Held
179MCall Options Held
721KPut Options Held
489K-
Vanguard Group Inc Valley Forge, PA21.7MShares$180 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$166 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ8.93MShares$74.1 Million5.64% of portfolio
-
Avoro Capital Advisors LLC New York, NY8.7MShares$72.2 Million1.06% of portfolio
-
State Street Corp Boston, MA7.81MShares$64.9 Million0.0% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.54B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...